Altamira Therapeutics (CYTO) Set to Announce Quarterly Earnings on Tuesday

Altamira Therapeutics (NASDAQ:CYTO) will be issuing its quarterly earnings results before the market opens on Tuesday, September 24th.

Altamira Therapeutics Price Performance

CYTO stock traded down $0.04 during midday trading on Friday, hitting $0.71. 53,763 shares of the company’s stock were exchanged, compared to its average volume of 895,984. The firm has a 50 day moving average price of $1.00 and a 200-day moving average price of $1.39. Altamira Therapeutics has a 12-month low of $0.71 and a 12-month high of $17.20.

Altamira Therapeutics Company Profile

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.